A Phase II, Multi-Centre, Placebo-Controlled, Randomised Study of the Safety, Pharmacokinetics and Antiviral Activity of BIT225 in Combination with Pegylated Interferon alfa-2b and Ribavirin in Patients with Hepatitis C Virus Infection.
Latest Information Update: 16 Jul 2019
At a glance
- Drugs BIT 225 (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Biotron
- 04 Jul 2016 Status changed from active, no longer recruiting to completed.
- 30 Sep 2015 Updated interim results published in the Media Release.
- 06 Jul 2015 Interim results published in the Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History